Death during follow-up | p valuea | |||
---|---|---|---|---|
No | At 5 years | At 15 years | ||
N = 1091 | N = 121 | N = 262 | ||
Age, year, mean (SD) | 67.3 (9.9) | 71.6 (8.7) | 71.8 (8.5) | < 0.001 |
Women, n (%) | 610 (55.9) | 47 (38.8) | 112 (42.8) | < 0.001 |
Education level, n (%) | ||||
Low | 291 (26.7) | 39 (32.2) | 79 (30.2) | |
Intermediate | 361 (33.1) | 38 (31.4) | 94 (35.9) | |
High | 439 (40.2) | 44 (36.4) | 89 (34.0) | 0.17 |
MMSE score, mean (SD) | 23.0 (5.2) | 19.8 (6.0) | 21.0 (6.0) | < 0.001 |
Cognitive stage, n (%) | ||||
Cognitively unimpaired | 326 (29.9) | 11 (9.1) | 36 (13.7) | |
Mild cognitive impairment | 418 (38.3) | 51 (42.2) | 120 (45.8) | |
Dementia | 347 (31.8) | 59 (48.8) | 106 (40.5) | < 0.001 |
APOE4 carriers, n (%) | 414 (42.0) | 35 (36.8) | 97 (44.3) | 0.53 |
Heavy alcohol consumption, n (%)b | 66 (7.1) | 11 (10.7) | 21 (9.9) | 0.32 |
Smokers, n (%) | 92 (9.7) | 14 (13.1) | 31 (14.0) | 0.06 |
Dyslipidemia, n (%) | 298 (30.0) | 46 (39.7) | 89 (36.2) | 0.06 |
Hypertension, n (%) | 430 (43.1) | 62 (53.9) | 132 (53.4) | 0.004 |
Diabetes mellitus, n (%) | 146 (14.7) | 25 (21.6) | 45 (18.4) | 0.15 |
A/T/N profiles, n (%) | ||||
A − /T − /N − | 374 (34.3) | 25 (20.7) | 44 (16.8) | |
A − /T − /N + | 46 (4.2) | 8 (6.6) | 10 (3.8) | |
A − /T + | 126 (11.6) | 12 (9.9) | 36 (13.7) | |
A + /T − | 163 (14.9) | 24 (19.8) | 51 (19.5) | |
A + /T + | 382 (35.0) | 52 (43.0) | 121 (46.2) | < 0.001 |
CSF biomarkers, pg/mL, mean (SD) | ||||
Aβ42 | 782.3 (344.7) | 616.5 (273.7) | 590.0 (267.6) | ≤ 0.001 |
Aβ40 | 11,950 (4931) | 10,443 (4633) | 11,885 (5839) | 0.90 |
Aβ42/40 ratio | 0.078 (0.051) | 0.074 (0.039) | 0.067 (0.036) | 0.02 |
Tau | 387.8 (264.9) | 567.2 (361.5) | 518.6 (322.5) | ≤ 0.001 |
p-Tau181 | 61.1 (38.0) | 78.0 (43.8) | 78.6 (40.7) | ≤ 0.001 |
p-Tau181/Aβ42 ratio | 0.11 (0.11) | 0.17 (0.14) | 0.17 (0.13) | ≤ 0.001 |